Zydus Cadila gets USFDA’s nod for Amiloride Hydrochloride Tablets

11 Aug 2015 Evaluate

Zydus Cadila has received the final approval from the USFDA to market Amiloride Hydrochloride Tablets USP, 5 mg. The drug falls in the diuretics segment. The group now has 101 approvals and has so far filed over 260 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.

Zydus Lifesciences Share Price

910.75 5.90 (0.65%)
16-Feb-2026 11:10 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1701.00
Dr. Reddys Lab 1265.75
Cipla 1345.90
Zydus Lifesciences 910.75
Lupin 2226.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×